摘要:
The present invention relates to a prooxidant synergistic combination to treat B-cell malignancies, such as B cell lymphomas, which comprises a thioredoxin reductase inhibitor, selected from a group comprising auranofin and SK053, and L- or D-ascorbate. The combination of the invention exerts synergistic cytotoxic effects towards malignant, but not normal B cells.